UNASSIGNED: Medical Information Mart for Intensive Care (MIMIC) IV databases were used for this retrospective study. The primary outcome of this study was 30-day all-cause mortality. The subgroup analysis of was the relationship between the combined use of vasopressors and inotropes and 30-day all-cause mortality.
UNASSIGNED: A total of 2,216 patients diagnosed with CS were enrolled in this study. The non-survivors group was more likely to be older, presented with chronic kidney disease, have a lower systolic blood pressure, lower heart rate, and higher respiratory rate (all p < 0.05). In the multivariate Cox regression analysis, only dopamine [HR (95%CI): 1.219 (1.003-1.482)], norepinephrine [HR (95%CI): 2.528 (1.829-3.493)], and milrinone [HR (95%CI): 0.664 (0.512-0.861)] remained an independent predictor for 30-day all-cause mortality. Furthermore, a subgroup analysis was performed and found that no statistically significant difference between no vasopressor/inotrope use and 1 vasopressor/inotrope use (p = 0.107). Meanwhile, a substantial deterioration of cumulative survival was observed when a combination of 2 or more vasopressors/inotropes was used in CS patients in comparison with no vasopressor/inotrope or only 1 vasopressor/inotrope use (all p < 0.05).
UNASSIGNED: Using vasopressors/inotropes agents was associated with a higher risk of 30-day all-cause mortality in CS patients. In addition, only milrinone was associated with a better prognosis among the available vasoactive agents.
■重症监护医学信息集市(MIMIC)IV数据库用于本回顾性研究。这项研究的主要结果是30天全因死亡率。的亚组分析是血管加压药和肌力强化剂的联合使用与30天全因死亡率之间的关系。
■本研究共纳入2,216例诊断为CS的患者。非幸存者组年龄更大,患有慢性肾病,收缩压较低,降低心率,和更高的呼吸频率(所有p<0.05)。在多元Cox回归分析中,仅多巴胺[HR(95CI):1.219(1.003-1.482)],去甲肾上腺素[HR(95CI):2.528(1.829-3.493)],米力农[HR(95CI):0.664(0.512-0.861)]仍然是30日全因死亡率的独立预测因子.此外,我们进行了一项亚组分析,发现没有使用血管加压药/抗张剂和使用1次血管加压药/抗张剂之间无统计学差异(p=0.107).同时,当CS患者使用2种或更多种血管加压药/肌力强化剂的组合时,与不使用血管加压药/肌力强化剂或仅使用1种血管加压药/肌力强化剂相比,观察到累积生存率显著下降(均p<0.05).
■在CS患者中,使用血管加压药/促效药与30天全因死亡的风险更高相关。此外,在现有的血管活性药物中,只有米力农与较好的预后相关.